I hope the ATM fees are refunded

According to NHS Providers, a group that represents 97% of hospital, mental health, community and ambulance service trusts in England, the NHS needs an immediate cash injection of between £200 and £350 million to manage the risk associated with a projected “bad” winter in England. For some encouraging reading, see their Winter Warning publication. So, winter coming, there’s a physician and nurse shortage, A&E (think emergency room for our American readers) wait times are up, and previous programs have not produced enough efficiencies. Any good news? Yes. Apparently planning and support is “considerably more developed” than last year. Great, there’s a plan. Here’s hoping the winter is not too bad. Keep calm and show me the money.

Now don't be stingy. Share this.Share on FacebookShare on Google+Tweet about this on TwitterShare on LinkedIn

A not-so-NICE decision for Eisai

Earlier this week the National Institute for Health and Care Excellence (NICE) said it is not recommending NHS funding for Eisai’s Kisplyx (lenvatinib) plus everolimus for treating advanced renal cell carcinoma in adults who have had one previous vascular endothelial growth factor (VEGF)-targeted therapy. The reason? “The cost-effectiveness estimates compared with all comparators were much more than what NICE normally considers acceptable (£30,000 per quality-adjusted life year gained).” Gotta hand it to NICE, a rule is a rule. The decision did recognize there was a 10.1 month improvement in life expectancy, but this figure was based on a small sample size in the clinical trials. While we’re not market access experts, good chance Eisai will be firing up some RWE/HEOR/Late-phase studies fairly soon.

Now don't be stingy. Share this.Share on FacebookShare on Google+Tweet about this on TwitterShare on LinkedIn

Safe T first

Yay, we get to write another article about fewer needles in the lives of diabetics! Researchers in London are working on an immunotherapy approach to slow down the progression of Type I Diabetes, which would ideally result in a future where those diabetics won’t have to inject insulin daily. The disease works by attacking insulin-producing cells, so the scientists decided to try to get the lazy part of the immune system that wasn’t stopping that—regulatory T cells—to stop playing video games and get a job! (Sorry. Too close to home?) The scientists proved the safety of this approach in a recent Phase I study, so it will be a while before anything is marketed to the general public, but we just think this immunotherapy stuff is the bee’s knees.

Now don't be stingy. Share this.Share on FacebookShare on Google+Tweet about this on TwitterShare on LinkedIn

UK to dramatically improve mental health care

Longtime Insight City readers beware, we really can’t use our normal voice/style for this article. But don’t think we didn’t think about it. Earlier this week UK NHS Health Secretary Jeremy Hunt launched a plan to expand the country’s mental health treatment efforts. And not just any plan. The NHS has committed £1.3 billion to transform mental health services, with a pledge to: (1) treat an extra 1 million patients by 2020 by hiring ~21,000 more workers, (b) provide services 7 days a week, 24 hours a day, and (iii) integrate mental and physical health services for the first time. Yep, 1.3 billion pounds. That’s like 650,000 tons of money. You do the math. To get you up-to-speed, see the most prevalent mental illnesses in the UK here.

Now don't be stingy. Share this.Share on FacebookShare on Google+Tweet about this on TwitterShare on LinkedIn

1. About that new drug you wanted…

Beginning in April of this year, NHS England will have the ability to withhold patient access to select approved medicines, according to The Times. Even if NICE considers a new drug of appropriate value, it may be withheld or rationed if it costs the NHS more than £20 million per year. While this might not be too alarming for those seeking help to lower cholesterol, the prospect of a drug being withheld for a rare disease – even if it is considered good value – is no bueno. Or what if one of the many potential Alzheimer’s drugs in development works? The size of the addressable patient population could make the £20 million threshold look puny. Stay tuned for more unpopular decisions to come.

Now don't be stingy. Share this.Share on FacebookShare on Google+Tweet about this on TwitterShare on LinkedIn

2. Who’s stepping up to the digital plate?

The NHS that’s who. UK Health Secretary Jeremy Hunt has unveiled plans to “fast track digital excellence” including a further round of digital excellence centres and “instant access” to a personal online health record. The NHS will select 12 “global exemplars” that could receive up to £10 million to support their pioneering efforts. The plan will also invest heavily in training healthcare workers on how to use digital technologies. One example: A library of NHS-approved health apps to guide patient choice. They will also be advising on other wearable devices, to ensure people can select reputable and effective products to monitor and improve their health. Brilliant.

Now don't be stingy. Share this.Share on FacebookShare on Google+Tweet about this on TwitterShare on LinkedIn